Clinical trials
Lung Cancer (Suspected or Confirmed) clinical trials
Below are recruiting lung cancer (suspected or confirmed) clinical trials, each written for real people, not researchers. We’re tracking 6,580 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06072911Recruiting
Men's health after prostate cancer surgery study
This study looks at how men recover control of urine and sexual function after prostate removal surgery. It also tests if a 12-week exercise program can help improve these functions.
Edmonton, AlbertaAges 18 years+ - NCT06058819Recruiting
New blood test to guide antibiotic use in newborns
This study is testing a new blood test to see if it can help doctors decide when to use antibiotics for newborns who may have a late-onset infection. The goal is to reduce unnecessary antibiotic use.
BronAges 1 week–2 weeks - NCT06065371RecruitingPhase 1
Sacituzumab govitecan plus capecitabine for advanced GI cancers
This trial tests a combination of two drugs—sacituzumab govitecan (targeted therapy) and capecitabine (chemotherapy)—for people with advanced stomach, colon, or pancreatic cancer that has stopped responding to standard treatments.
Detroit, MichiganAges 18 years+ - NCT06080113Enrolling by invitation
Focal radioactive seed implant for prostate cancer
This trial is testing a new way to treat prostate cancer by placing a tiny radioactive seed directly into the main tumor. It's for men with early-stage, slow-growing cancer who have just one visible tumor on MRI.
HerlevAges 18–80 - NCT04656041RecruitingPhase 2
Test chemo with radiation for gastroesophageal cancer
This Phase 2 study tests a combination of chemotherapy (5-FU/leucovorin plus irinotecan and oxaliplatin) together with radiation for certain types of esophagus/stomach-junction cancer. It may help shrink tumors and control cancer that is locally advanced but not spread to distant organs.
Boston, MassachusettsAges 18 years+ - NCT06033196RecruitingPhase 2
Tocilizumab after lung transplant
This study tests whether the drug tocilizumab can help prevent your body from rejecting a new lung after transplant. It might help improve the success of your transplant by reducing immune system activity.
Phoenix, ArizonaAges 12–75 - NCT06036719Recruiting
Lung scarring study from childhood to old age
This trial looks at different types of lung scarring (called interstitial lung disease) to better understand the condition across all ages. It also includes family members of people with certain genetic mutations that affect the lungs.
Paris, Île-de-France RegionAges Any age - NCT06038578RecruitingPhase 2
TRK-950 with standard chemo for advanced stomach cancer
This trial tests a new drug, TRK-950, added to standard chemotherapy (ramucirumab and paclitaxel) for people with advanced stomach or gastroesophageal junction cancer that has worsened after previous treatment. The goal is to see if this combination can help shrink tumors or slow disease progression.
Duarte, CaliforniaAges 18 years+ - NCT06055439RecruitingPhase 1/Phase 2
CAR T cell therapy for GI cancers
This trial tests a new type of immunotherapy called CAR T cells that target a protein (CDH17) found on certain stomach, colon, and rectal cancers. It's designed for people whose cancer has spread and has been treated before.
Atlanta, GeorgiaAges 18–85 - NCT04428554RecruitingPhase 2
Radiation to control bladder cancer spread after no growth
This trial tests whether giving focused radiation (SBRT) to a few remaining metastatic spots can stop bladder cancer from progressing after initial chemotherapy or immunotherapy has worked. It may help patients who still have up to three remaining distant lesions but are not getting worse.
AlbiAges 18 years+ - NCT06037980RecruitingPhase 2/Phase 3
Chemotherapy before surgery for high-risk bile duct cancer
This trial tests whether receiving chemotherapy (cisplatin, gemcitabine, and nab-paclitaxel) before surgery can improve outcomes for people with high-risk bile duct or gallbladder cancer. It compares this approach to going straight to surgery.
AnconaAges 18–75 - NCT06052683Recruiting
Comparing radiation side effects for low-risk prostate cancer
This trial compares two types of radiation therapy (SBRT and LDR brachytherapy) for men with low-risk or favorable intermediate-risk prostate cancer. The goal is to see which treatment causes fewer side effects.
Québec, QuebecAges 18 years+ - NCT06048835Recruiting
Studying tumor cells in breast cancer patients
This trial looks at tumor cells in the blood of women with breast cancer to understand them better. It may help doctors learn more about how the disease spreads.
Pavia, LombardyAges 18–90 - NCT06040970RecruitingPhase 1/Phase 2
Sacituzumab govitecan plus cisplatin for recurrent ovarian/endometrial cancer
This trial tests a combination of two drugs—sacituzumab govitecan and cisplatin—for women with ovarian or endometrial cancer that has come back after responding to platinum chemotherapy. The goal is to see if the combination works better than current options.
New York, New YorkAges 18 years+ - NCT06038032Recruiting
Healthy habits after endometrial cancer
This trial tests a lifestyle program to help people who have had endometrial cancer lose weight and improve their health. It uses a Fitbit app, group video sessions, and other tools to support healthy changes.
Edmonton, AlbertaAges 18 years+ - NCT06052332Recruiting
Comparing two pre-surgery treatments for older adults with rectal cancer
This study compares two approaches to treating rectal cancer in people age 70 and older who have not yet had surgery. One approach gives chemotherapy and radiation before surgery, and the other adds more chemotherapy after radiation. The goal is to find which plan works better with fewer side effects.
Antwerp, AntwerpenAges 70 years+ - NCT06039371RecruitingPhase 2
High dose testosterone during chemo for advanced prostate cancer
This trial tests if adding high doses of testosterone to standard chemotherapy (etoposide and carboplatin) can make the chemo work better in men whose prostate cancer has stopped responding to other treatments. It aims to see if this approach can shrink tumors or slow cancer growth.
Seattle, WashingtonAges 18 years+ - NCT05672615Recruiting
Mood changes during bladder cancer treatment with BCG
This study looks at how bladder cancer treatment with BCG may affect mood and emotional well-being. It may help doctors understand which patients experience mood changes during care.
Washington D.C., District of ColumbiaAges 18 years+ - NCT05984875Recruiting
Immune system study for ovarian cancer
This study looks at how the immune system works in people with epithelial ovarian cancer. It aims to understand the immune landscape around the tumor, which could lead to better treatments in the future.
BellinzonaAges 18 years+ - NCT05773859RecruitingPhase 1/Phase 2
Vaccination before surgery to treat advanced ovarian cancer
This trial studies a vaccine made from your immune cells (dendritic cell vaccine) given before chemotherapy and surgery. It aims to help your body recognize and fight ovarian cancer more effectively in people whose cancer is advanced and spread.
Nijmegen, GelderlandAges 18 years+ - NCT05800275RecruitingPhase 2
Tucatinib and capecitabine plus spinal trastuzumab for HER2+ cancer
This Phase 2 trial tests a combination of tucatinib and capecitabine (taken by mouth) plus trastuzumab delivered into the spinal fluid, to treat breast cancer that has spread to the leptomeninges (lining around the brain/spinal cord). It may help reduce cancer activity in the spinal fluid and improve symptoms.
BordeauxAges 18 years+ - NCT05910398RecruitingPhase 3
Extending anti-HER2 treatment after breast cancer surgery
This Phase 3 trial tests whether continuing or pausing the anti-HER2 medicine pyrotinib after surgery can lower the chance that invasive HER2-positive breast cancer comes back. It may help people who have recently finished trastuzumab or T-DM1 and are well enough to take tablets.
ShanghaiAges 18 years+ - NCT05850182Recruiting
Lifestyle program for metastatic prostate cancer on hormone therapy
This trial studies whether a structured lifestyle intervention (such as exercise and related behavior changes) can benefit people with metastatic prostate cancer who are currently on hormone treatment. It may help by improving health and functioning while you continue standard cancer therapy.
BellinzonaAges 18 years+ - NCT06022822RecruitingPhase 2
Urolithin A supplement before prostate cancer surgery
This trial tests whether taking a supplement called urolithin A for a few weeks before prostate removal surgery can help. The supplement comes from pomegranates and may slow cancer growth. You may qualify if you have prostate cancer, are planning surgery within 3-6 weeks, and have not had prior treatment like hormone therapy.
Los Angeles, CaliforniaAges 18 years+
Hear when a new Lung Cancer (Suspected or Confirmed) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for lung cancer (suspected or confirmed)?
- Yes. Clin2 currently lists 6,580 recruiting lung cancer (suspected or confirmed) studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a lung cancer (suspected or confirmed) trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a lung cancer (suspected or confirmed) trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.